Cargando…

Serial change of C1 inhibitor in patients with sepsis: a prospective observational study

BACKGROUND: C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirose, Tomoya, Ogura, Hiroshi, Takahashi, Hiroki, Ojima, Masahiro, Jinkoo, Kang, Nakamura, Youhei, Kojima, Takashi, Shimazu, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032562/
https://www.ncbi.nlm.nih.gov/pubmed/30002833
http://dx.doi.org/10.1186/s40560-018-0309-5
_version_ 1783337525562048512
author Hirose, Tomoya
Ogura, Hiroshi
Takahashi, Hiroki
Ojima, Masahiro
Jinkoo, Kang
Nakamura, Youhei
Kojima, Takashi
Shimazu, Takeshi
author_facet Hirose, Tomoya
Ogura, Hiroshi
Takahashi, Hiroki
Ojima, Masahiro
Jinkoo, Kang
Nakamura, Youhei
Kojima, Takashi
Shimazu, Takeshi
author_sort Hirose, Tomoya
collection PubMed
description BACKGROUND: C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeability and anti-inflammatory functions. The objective of this study was to clarify the serial change of C1-INH in patients with sepsis and evaluate the relationship with the shock severity. METHODS: This was a single-center, prospective, observational study. We serially examined C1-INH activity values (normal range 70–130%) in patients with sepsis admitted into the intensive care unit of the Trauma and Acute Critical Care Center at Osaka University Hospital (Osaka, Japan) during the period between January 2014 and August 2015. We defined “refractory shock” as septic shock unresponsive to conventional therapy such as adequate fluid resuscitation and vasopressor therapy to maintain hemodynamics. RESULTS: Serial changes of C1-INH were evaluated in 40 patients with sepsis (30 men, 10 women; 30 survivors, 10 non-survivors; mean age, 70 ± 13.5 years). We divided the patients into three groups: non-shock group (n = 14), non-refractory shock group (n = 13), and refractory shock group (n = 13: 3 survivors, 10 non-survivors). In the non-shock group, C1-INH was 107.3 ± 26.5% on admission and 104.2 ± 22.3% on day 1, and it increased thereafter to 128.1 ± 26.4% on day 3, 138.3 ± 21.2% on day 7, and 140.3 ± 12.5% on day 14 (p < 0.0001). In the non-refractory shock group, C1-INH was 113.9 ± 19.2% on admission, 120.2 ± 23.0% on day 1, 135.7 ± 19.9% on day 3, 138.8 ± 17.2% on day 7, and 137.7 ± 10.7% on day 14 (p < 0.0001). In the refractory shock group, C1-INH was 96.7 ± 15.9% on admission, 88.9 ± 22.3% on day 1, 119.8 ± 39.6% on day 3, 144.4 ± 21.1% on day 7, and 140.5 ± 24.5% on day 14 (p < 0.0001). The difference between these three groups was statistically significant (p < 0.0001). C1-INH in non-survivors did not increase significantly during their clinical course (p = 0.0690). CONCLUSIONS: In refractory shock patients with sepsis, the values of C1-INH activity were lower (especially in non-survivors) on admission and day 1 as compared with non-shock and non-refractory shock patients.
format Online
Article
Text
id pubmed-6032562
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60325622018-07-12 Serial change of C1 inhibitor in patients with sepsis: a prospective observational study Hirose, Tomoya Ogura, Hiroshi Takahashi, Hiroki Ojima, Masahiro Jinkoo, Kang Nakamura, Youhei Kojima, Takashi Shimazu, Takeshi J Intensive Care Research BACKGROUND: C1 inhibitor (C1-INH), which belongs to the superfamily of serine protease inhibitors, regulates the complement system and also the plasma kallikrein-kinin, fibrinolytic, and coagulation systems. The biologic activities of C1-INH can be divided into the regulation of vascular permeability and anti-inflammatory functions. The objective of this study was to clarify the serial change of C1-INH in patients with sepsis and evaluate the relationship with the shock severity. METHODS: This was a single-center, prospective, observational study. We serially examined C1-INH activity values (normal range 70–130%) in patients with sepsis admitted into the intensive care unit of the Trauma and Acute Critical Care Center at Osaka University Hospital (Osaka, Japan) during the period between January 2014 and August 2015. We defined “refractory shock” as septic shock unresponsive to conventional therapy such as adequate fluid resuscitation and vasopressor therapy to maintain hemodynamics. RESULTS: Serial changes of C1-INH were evaluated in 40 patients with sepsis (30 men, 10 women; 30 survivors, 10 non-survivors; mean age, 70 ± 13.5 years). We divided the patients into three groups: non-shock group (n = 14), non-refractory shock group (n = 13), and refractory shock group (n = 13: 3 survivors, 10 non-survivors). In the non-shock group, C1-INH was 107.3 ± 26.5% on admission and 104.2 ± 22.3% on day 1, and it increased thereafter to 128.1 ± 26.4% on day 3, 138.3 ± 21.2% on day 7, and 140.3 ± 12.5% on day 14 (p < 0.0001). In the non-refractory shock group, C1-INH was 113.9 ± 19.2% on admission, 120.2 ± 23.0% on day 1, 135.7 ± 19.9% on day 3, 138.8 ± 17.2% on day 7, and 137.7 ± 10.7% on day 14 (p < 0.0001). In the refractory shock group, C1-INH was 96.7 ± 15.9% on admission, 88.9 ± 22.3% on day 1, 119.8 ± 39.6% on day 3, 144.4 ± 21.1% on day 7, and 140.5 ± 24.5% on day 14 (p < 0.0001). The difference between these three groups was statistically significant (p < 0.0001). C1-INH in non-survivors did not increase significantly during their clinical course (p = 0.0690). CONCLUSIONS: In refractory shock patients with sepsis, the values of C1-INH activity were lower (especially in non-survivors) on admission and day 1 as compared with non-shock and non-refractory shock patients. BioMed Central 2018-07-04 /pmc/articles/PMC6032562/ /pubmed/30002833 http://dx.doi.org/10.1186/s40560-018-0309-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hirose, Tomoya
Ogura, Hiroshi
Takahashi, Hiroki
Ojima, Masahiro
Jinkoo, Kang
Nakamura, Youhei
Kojima, Takashi
Shimazu, Takeshi
Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
title Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
title_full Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
title_fullStr Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
title_full_unstemmed Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
title_short Serial change of C1 inhibitor in patients with sepsis: a prospective observational study
title_sort serial change of c1 inhibitor in patients with sepsis: a prospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032562/
https://www.ncbi.nlm.nih.gov/pubmed/30002833
http://dx.doi.org/10.1186/s40560-018-0309-5
work_keys_str_mv AT hirosetomoya serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT ogurahiroshi serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT takahashihiroki serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT ojimamasahiro serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT jinkookang serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT nakamurayouhei serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT kojimatakashi serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy
AT shimazutakeshi serialchangeofc1inhibitorinpatientswithsepsisaprospectiveobservationalstudy